Skip to content

Efficacy Assessment of Gluten Free Cupcakes

Development and Efficacy Assessment of Aglutenic Product to Improve the Nutritional Status of Celiac Children

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06359613
Enrollment
75
Registered
2024-04-11
Start date
2019-10-03
Completion date
2020-01-03
Last updated
2024-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Celiac Disease in Children

Keywords

gluten sensitivity children nutritional status food choices

Brief summary

Randomized controlled trial will be conducted after getting informed consent form from each study participant meeting inclusion criteria (n=70, 35 control group +35 intervention group, 3-8years of age). After consumer acceptance against various attributes of aglutenic cupcake, the product will be provided in polyethylene bags containing 28 cupcakes (35gm by weight/cupcake, 2 cupcakes for each day) providing approximately 20% daily value (DV) of energy. Cupcakes of equal weight and size made with rice flour (mostly used recipe) will be provided to the control group. Further product will be provided on follow-up visits. The compliance to a gluten free diet GFD and supplemented product will be confirmed by a Food Frequency Questionnaire (FFQ).

Detailed description

Raw Material/ Preparation of flour blends for aglutenic (gluten free) cupcakes: Sorghum, chickpea, Flaxseed and Almond rich in healthy nutrients will be purchased from the local market. All these ingredients was ground into fine powder using uncontaminated grinder. Different flour blends was prepared by substituting whole wheat flour with Sorghum, Chickpea, Flaxseed and Almond flour at different replacement levels. The efficacy study protocol was approved by the Bioethics Committee for randomized controlled trial (RCT). Written informed consent was obtained by the parents of children or their legal guardian. Target population: Celiac Disease/gluten sensitive patients (n= 70, 35 control + 35 intervention) was recruited according to European Society for Pediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) criteria. Inclusion criteria: In accordance with the inclusion criteria, boys and girls suffering from celiac disease was recruited: * Positive trans-glutaminase antibody (tTG) as currently recommended test is the serum Immunoglobulin A (IgA) tissue trans-glutaminase antibody (tTG). The test has a sensitivity and specificity of greater than 90%. * Clinical response to gluten free diet * In the age range of 3-8 years Exclusion Criteria: * Patients on any other designed diet * Taking vitamins and mineral supplements * Individuals presenting with any other intestinal inflammatory disease, malignant diseases, chronic infections, thyroid, renal or hepatic alterations * Taking drugs known to effect lipid and /or carbohydrate metabolism will be excluded from the study. Effect of interventional product on nutritional status of participants will be assessed through anthropometric measurements, gastrointestinal complaints and following hematological indices; * Complete Blood Count (CBC) WBCs, RBCs, MCV, Hb. , Hct. , Platelets * Total Protein * Lipid Profile HDL, LDL, VLDL, Cholesterol * SGPT, SGOT * Serum Electrolytes (Na ,Ca, K)

Interventions

DIETARY_SUPPLEMENTnutrient rich food product

Cupcakes from flour blends of Sorghum, chickpea, Flaxseed and Almond will be prepared and flour concentration will be so adjusted to provide \>20% daily value of nutrients for children of 3-8 years of age. 2 cupcakes/ day, 35g each will be provided to participants for 12 weeks.

DIETARY_SUPPLEMENTfood product

Cupcakes from usually used gluten free rice flour will be prepared. 2 cupcakes/ day, 35g each will be provided to participants for 12 weeks.

Sponsors

University of Veterinary and Animal Sciences, Lahore - Pakistan
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

The product will be provided to intervention group (n=50) in polyethylene bags containing 28 cupcakes (35gm by weight/cupcake, 2/day) providing approximately 20%DV of energy. Cupcakes of equal weight and size made with rice flour (mostly used recipe) will be provided to the control group (n=50)

Eligibility

Sex/Gender
ALL
Age
3 Years to 8 Years
Healthy volunteers
No

Inclusion criteria

* Positive tissue trans-glutaminase antibody (tTG) * Clinical response to gluten free diet

Exclusion criteria

* Vitamins and mineral supplements * Intestinal inflammatory diseases * Malignant diseases of intestines * Chronic infections, * Thyroid, renal or hepatic alterations * Celiac patients with diabetes * Taking drugs known to effect lipid and /or carbohydrate metabolism

Design outcomes

Primary

MeasureTime frameDescription
Serum Electrolytes12 weeksSodium mmol/L Calcium mg/dL Potassium mmol/L
Body Mass Index (BMI)12 weeksBMI will be calculated by using standard formula as weight in kilograms divided by height in meter square kg/m2. World Health Organization (WHO) standard growth charts, designed separately for boys and girls will be used as a research tool to assess the nutritional status.
Body Weight12 weeksBody weight (in kilograms) will be measured using a weight machine with standardization done after every 20 readings.
Height of the patients12 weeksHeight (in centimeters) will be measured (without shoes) in the position, back and hips touching the wall by using wall mounted stedio-meter
Mid upper Arm Circumference (MUAC)12 weeksMid-upper arm circumference (MUAC) in centimeters will be measured midpoint between the acromion process of the scapula and the tip of the elbow.
Complete Blood Count (CBC)12 weeksWhite Blood Cells 10\^9/L Red Blood Cells million/mm3 Mean Corpuscular Volume 10\^6/µL Hemoglobin g/dL Hematocrit % Platelets 10\^9/L
Total Protein12 weeksSerum Total Protein g/dL
Lipid Profile12 weeksHigh Density Lipoproteins mg/dL Low Density Lipoproteins mg/dL Very Low-Density Lipoproteins mg/dL Serum Total Cholesterol mg/dL
Liver Enzymes12 weeksserum glutamic-pyruvic transaminase SGPT- U/L, serum glutamic-oxaloacetic transaminase SGOT-U/L

Secondary

MeasureTime frameDescription
Gastrointestinal Symptoms12 weeksRate of diarrhea, constipation, Severity of abdominal pain, steatorrhea, flatulence and appetite will be monitored by using Gastrointestinal Rating Scale with addition of Steatorrhea.

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026